Skip to main content
SpringerLink
Log in

Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

To examine the prognostic significance of minimal residual disease (MRD) in t(8;21) acute myeloid leukemia (AML), 96 bone marrow samples from 26 Japanese patients in complete remission (CR) were analyzed regarding the RUNX1/MTG8 transcript using real-time reverse transcriptase polymerase chain reaction assay. All patients were treated with intensive chemotherapy. The median copy number of the RUNX1/MTG8 transcript, measured after each treatment course decreased over time. However, an increase in the MRD level was documented in three patients after the second consolidation, and all of them subsequently relapsed. The relapse-free survival (RFS) did not differ between the patients whose MRD levels were below or above 1,000 copies/µg after the first consolidation, with respective 2-year rates of 62 and 86% (P = 0.21). With respect to the MRD level after induction therapy, our data also failed to show any favorable effect of a lower MRD on RFS. Although these findings need to be confirmed with a larger number of patients, our data indicate that the MRD level at a given time during the early course in CR does not predict the outcome in Japanese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferrara F, Del Vecchio L. Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity. Haematologica. 2002;87:306–19.

    CAS  PubMed  Google Scholar 

  2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–33.

    CAS  PubMed  Google Scholar 

  3. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–36.

    Article  CAS  PubMed  Google Scholar 

  4. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986–94.

    Article  CAS  PubMed  Google Scholar 

  5. Krauter J, Gorlich K, Ottmann O, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol. 2003;21:4413–22.

    Article  CAS  PubMed  Google Scholar 

  6. Tobal K, Newton J, Macheta M, et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood. 2000;95:815–9.

    CAS  PubMed  Google Scholar 

  7. Leroy H, de Botton S, Grardel-Duflos N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia. 2005;19:367–72.

    Article  CAS  PubMed  Google Scholar 

  8. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2006;20:87–94.

    Article  CAS  PubMed  Google Scholar 

  9. Weisser M, Haferlach C, Hiddemann W, Schnittger S. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia. 2007;21:1177–82.

    Article  CAS  PubMed  Google Scholar 

  10. Narimatsu H, Yokozawa T, Iida H, et al. Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan. Leukemia. 2008;22:428–32.

    Article  CAS  PubMed  Google Scholar 

  11. Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705–17.

    Article  PubMed  Google Scholar 

  12. Osumi K, Fukui T, Kiyoi H, et al. Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma. 2002;43:2291–9.

    Article  CAS  PubMed  Google Scholar 

  13. Nanri T, Matsuno N, Kawakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia. 2005;19:1361–6.

    Article  CAS  PubMed  Google Scholar 

  14. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791–9.

    Article  CAS  PubMed  Google Scholar 

  15. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904–11.

    Article  CAS  PubMed  Google Scholar 

  16. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA. 2000;97:7521–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We wish to thank all the staff and resident members of the participating institutions. A complete list of participating institutions appears in the Appendix.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan

    Hiroto Narimatsu, Akiyo Sawamoto & Isamu Sugiura

  2. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan

    Hiroto Narimatsu, Masamitsu Yanada & Tomoki Naoe

  3. Department of Hematology, Yamanashi Prefectural Central Hospital, Kofu, Japan

    Masaki Iino

  4. Department of Hematology, Okazaki City Hospital, Okazaki, Japan

    Takuji Ichihashi

  5. Department of Hematology/Oncology, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

    Toshiya Yokozawa

  6. Department of Hematology, Komaki City Hospital, Komaki, Japan

    Masaya Hayakawa

  7. Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan

    Hitoshi Kiyoi

  8. Department of Hematology, Yokkaichi Municipal Hospital, Yokkaichi, Japan

    Takaaki Takeo

  9. Department of Hematology, Meitetsu Hospital, Nagoya, Japan

    Hiroatsu Iida

  10. Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan

    Motohiro Tsuzuki

  11. Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya, Japan

    Ritsuro Suzuki

Authors
  1. Hiroto Narimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaki Iino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuji Ichihashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshiya Yokozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaya Hayakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hitoshi Kiyoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takaaki Takeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akiyo Sawamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroatsu Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Motohiro Tsuzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masamitsu Yanada
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tomoki Naoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ritsuro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Isamu Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroto Narimatsu.

Appendix

Appendix

This study was conducted at the following institutions: Toyohashi Municipal Hospital, Toyohashi; Yamanashi Prefectural Central Hospital, Kofu; National Hospital Organization Nagoya Medical Center, Nagoya; Komaki City Hospital, Komaki; Nagoya University Hospital, Nagoya; Yokkaichi Municipal Hospital, Yokkaichi; Okazaki City Hospital, Okazaki; Meitetsu Hospital, Nagoya; Fujita Health University Hospital, Toyoake, Japan.

About this article

Cite this article

Narimatsu, H., Iino, M., Ichihashi, T. et al. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan. Int J Hematol 88, 154–158 (2008). https://doi.org/10.1007/s12185-008-0108-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-008-0108-1

Keywords

Search

Navigation